Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.61 |
| ▸ | BACE1 | P56817 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.56 |
| ▸ | APP | P05067 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 3/20 | 0.52 |
| ▸ | BCR | P11274 | 3/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | TTR | P02766 | 2/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.52 |
| ▸ | NQO2 | P16083 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.52 |
| ▸ | TUBB | P07437 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4821290 | 1.00 | GAA (0.62) | GAAHTTCYP1A1CYP1B1BACE1 | |
| SCHEMBL29090909 | 0.88 | GAA (0.54) | GAAHTTCYP1A1CYP1B1BACE1 | |
| SCHEMBL29728704 | 0.88 | GAA (0.54) | GAAHTTCYP1A1CYP1B1BACE1 | |
| SCHEMBL5598966 | 0.86 | F3 (0.66) | GAACYP1A1CYP1B1BACE1CYP1A2 | |
| SCHEMBL5598963 | 0.86 | F3 (0.66) | GAACYP1A1CYP1B1BACE1CYP1A2 | |
| SCHEMBL29606654 | 0.84 | F3 (0.63) | GAACYP1A1CYP1B1BACE1CYP1A2 | |
| SCHEMBL290940 | 0.84 | THRB (0.67) | GAACYP1A1CYP1B1BACE1CYP1A2 | |
| SCHEMBL290941 | 0.84 | THRB (0.67) | GAACYP1A1CYP1B1BACE1CYP1A2 | |
| SCHEMBL10601229 | 0.82 | CYP1A1 (0.59) | GAACYP1A1CYP1B1BACE1CYP1A2 | |
| SCHEMBL18386213 | 0.82 | BACE1 (0.62) | GAAHTTCYP1A1CYP1B1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2022158624-A1 | NOVEL BENZOPYRAN DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND ANTICANCER COMPOSITION COMPRISING SAME | 연세대학교 산학협력단 | 2022-07-28 | — | — | WO | disclosed |
| US-9856236-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2018-01-02 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| EP-2970210-B1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | Celon Pharma Sa (PL) | 2017-01-04 | — | — | EP | disclosed |
| EP-2970210-B1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | Celon Pharma Sa (PL) | 2017-01-04 | — | — | EP | disclosed |
| US-9290478-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-03-22 | — | — | US | disclosed |
| US-20080114061-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2008-05-15 | — | — | US | disclosed |
| US-7312241-B2 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| CN-101053558-A | Diphenylethylene compounds and uses thereof | CELGENE CORP (US) | 2007-10-17 | — | — | CN | disclosed |
| EP-1799634-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1603864-A4 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006026747-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1603864-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050107339-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-20050014727-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2004078144-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107339-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | GAA 1186/4885HTT 1033/4885CYP1A1 54/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | GAA 359/4885HTT 477/4885CYP1A1 3275/4885 |
| US-20080114061-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | GAA 1186/4885HTT 1033/4885CYP1A1 54/4885 |
| US-20050014727-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | GAA 1186/4885HTT 1033/4885CYP1A1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.